Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2014 1
2015 1
2016 2
2017 1
2018 2
2019 3
2020 7
2021 6
2022 7
2023 4

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Tuberculosis control.
Godfrey C, Andersen J, Mngqibisa R, Scott LE, Conradie F. Godfrey C, et al. Among authors: mngqibisa r. Lancet. 2016 Mar 19;387(10024):1157-8. doi: 10.1016/S0140-6736(16)00706-6. Lancet. 2016. PMID: 27025326 Free article. No abstract available.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Jaeger H, Overton ET, Richmond G, Rizzardini G, Andrade-Villanueva JF, Mngqibisa R, Hermida AO, Thalme A, Belonosova E, Ajana F, Benn PD, Wang Y, Hudson KJ, Español CM, Ford SL, Crauwels H, Margolis DA, Talarico CL, Smith KY, van Eygen V, Van Solingen-Ristea R, Vanveggel S, Spreen WR. Jaeger H, et al. Among authors: mngqibisa r. Lancet HIV. 2021 Nov;8(11):e679-e689. doi: 10.1016/S2352-3018(21)00185-5. Epub 2021 Oct 11. Lancet HIV. 2021. PMID: 34648734 Clinical Trial.
HIV and COPD: a conspiracy of risk factors.
Lalloo UG, Pillay S, Mngqibisa R, Abdool-Gaffar S, Ambaram A. Lalloo UG, et al. Among authors: mngqibisa r. Respirology. 2016 Oct;21(7):1166-72. doi: 10.1111/resp.12806. Epub 2016 May 30. Respirology. 2016. PMID: 27237114 Free article. Review.
Oral PrEP in adolescents in sub-Saharan Africa.
Archary M, Mngqibisa R. Archary M, et al. Among authors: mngqibisa r. Lancet Child Adolesc Health. 2020 Dec;4(12):854-855. doi: 10.1016/S2352-4642(20)30340-0. Epub 2020 Oct 24. Lancet Child Adolesc Health. 2020. PMID: 33222801 No abstract available.
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.
Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, Lalloo U, Masilela MSL, Moodley D, Hanley S, Fouche L, Louw C, Tameris M, Singh N, Goga A, Dheda K, Grobbelaar C, Kruger G, Carrim-Ganey N, Baillie V, de Oliveira T, Lombard Koen A, Lombaard JJ, Mngqibisa R, Bhorat AE, Benadé G, Lalloo N, Pitsi A, Vollgraaff PL, Luabeya A, Esmail A, Petrick FG, Oommen-Jose A, Foulkes S, Ahmed K, Thombrayil A, Fries L, Cloney-Clark S, Zhu M, Bennett C, Albert G, Faust E, Plested JS, Robertson A, Neal S, Cho I, Glenn GM, Dubovsky F, Madhi SA; 2019nCoV-501 Study Group. Shinde V, et al. Among authors: mngqibisa r. N Engl J Med. 2021 May 20;384(20):1899-1909. doi: 10.1056/NEJMoa2103055. Epub 2021 May 5. N Engl J Med. 2021. PMID: 33951374 Free PMC article. Clinical Trial.
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.
Avihingsanon A, Hughes MD, Salata R, Godfrey C, McCarthy C, Mugyenyi P, Hogg E, Gross R, Cardoso SW, Bukuru A, Makanga M, Badal-Aesen S, Mave V, Ndege BW, Fontain SN, Samaneka W, Secours R, Van Schalkwyk M, Mngqibisa R, Mohapi L, Valencia J, Sugandhavesa P, Montalban E, Munyanga C, Chagomerana M, Santos BR, Kumarasamy N, Kanyama C, Schooley RT, Mellors JW, Wallis CL, Collier AC, Grinsztejn B; A5288 Study team. Avihingsanon A, et al. Among authors: mngqibisa r. J Int AIDS Soc. 2022 Jun;25(6):e25905. doi: 10.1002/jia2.25905. J Int AIDS Soc. 2022. PMID: 36039892 Free PMC article.
Human Immunodeficiency Virus-associated Neurocognitive Impairment in Diverse Resource-limited Settings.
Robertson KR, Jiang H, Kumwenda J, Supparatpinyo K, Marra CM, Berzins B, Hakim J, Sacktor N, Campbell TB, Schouten J, Mollan K, Tripathy S, Kumarasamy N, La Rosa A, Santos B, Silva MT, Kanyama C, Firhnhaber C, Murphy R, Hall C, Marcus C, Naini L, Masih R, Hosseinipour MC, Mngqibisa R, Badal-Faesen S, Yosief S, Vecchio A, Nair A; AIDS Clinical Trials Group. Robertson KR, et al. Among authors: mngqibisa r. Clin Infect Dis. 2019 May 2;68(10):1733-1738. doi: 10.1093/cid/ciy767. Clin Infect Dis. 2019. PMID: 30219843 Free PMC article. Clinical Trial.
Integrative Multi-Omics Reveals Serum Markers of Tuberculosis in Advanced HIV.
Krishnan S, Queiroz ATL, Gupta A, Gupte N, Bisson GP, Kumwenda J, Naidoo K, Mohapi L, Mave V, Mngqibisa R, Lama JR, Hosseinipour MC, Andrade BB, Karakousis PC. Krishnan S, et al. Among authors: mngqibisa r. Front Immunol. 2021 Jun 8;12:676980. doi: 10.3389/fimmu.2021.676980. eCollection 2021. Front Immunol. 2021. PMID: 34168648 Free PMC article. Clinical Trial.
Antiretroviral Initiation at ≥800 CD4+ Cells/mm3 Associated With Lower Human Immunodeficiency Virus Reservoir Size.
Rasmussen TA, Ahuja SK, Kuwanda L, Vjecha MJ, Hudson F, Lal L, Rhodes A, Chang J, Palmer S, Auberson-Munderi P, Mugerwa H, Wood R, Badal-Faesen S, Pillay S, Mngqibisa R, LaRosa A, Hildago J, Petoumenos K, Chiu C, Lutaakome J, Kitonsa J, Kabaswaga E, Pala P, Ganoza C, Fisher K, Chang C, Lewin SR, Wright EJ. Rasmussen TA, et al. Among authors: mngqibisa r. Clin Infect Dis. 2022 Nov 14;75(10):1781-1791. doi: 10.1093/cid/ciac249. Clin Infect Dis. 2022. PMID: 35396591 Free PMC article.
35 results